Risk factors and stroke risk stratification for atrial fibrillation: Limitations and new possibilities

American Heart Journal

Volumn 156, Issue 1, 2008, Pages 1-3

  Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; D DIMER; FIBRIN; WARFARIN;

AORTA ATHEROSCLEROSIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; STROKE; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL ANALYSIS;

EID: 45649084073     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.02.020     Document Type: Editorial

References (16)

1. Lip G.Y., and Lim H.S. Atrial fibrillation and stroke prevention. Lancet Neurol 6 (2007) 981-993
2. Hughes M., and Lip G.Y.H. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemostat (2008)
3. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69 (2007) 546-554
4. Nieuwlaat R., Capucci A., Lip G.Y., et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 27 (2006) 3018-3026
5. Lip G.Y.H. Coronary artery disease and ischaemic stroke in atrial fibrillation. Chest 132 (2007) 8-10
6. Conway D.S., and Lip G.Y. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol 93 11 (2004) 1422-1425
7. Gage B.F., Walraven C.V., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 110 (2004) 2287-2292
8. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342 (1993) 1255-1262
9. Lip G.Y., Frison L., and Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 28 (2007) 752-759
10. Baruch L., Gage B.F., Horrow J., et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified. Stroke 38 (2007)
11. Fang M.C., Go A.S., Chang Y., et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 51 (2008) 810-815
12. Reitbrock S., Heeley E., Plumb J., et al. Chronic atrial fibrillation: incidence, prevalence and prediction of stroke using the Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 156 (2008) 57-64
13. Wang T.J., Massaro J.M., Levy D., et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290 (2003) 1049-1056
14. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke (2008) [in press]
15. Lip G.Y., Lane D., Van Walraven C., et al. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 37 (2006) 2294-2300
16. Nozawa T., Inoue H., Hirai T., et al. d-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 109 (2006) 59-65